Group items tagged

One Mind is inviting applications for its Rising Star Research Awards program, which seeks to fund early-career investigators who have demonstrated productivity and innovation in a scientific field that can be applied to the study of neuropsychiatric disorders such as anxiety, addiction, bipolar disorder, depression, posttraumatic stress, schizophrenia, traumatic brain injury, suicidality, and other serious psychiatric illnesses. To that end, grants of $300,000 over three years will be awarded in support of research proposals on any of a wide range of neuropsychiatric conditions. Studies focusing on bipolar disorder are of special interest, including applications that would advance therapeutics ranging from biomarkers to promising therapeutic modalities (e.g., neurostimulation). Examples of relevant research include those with potential to identify new biological mechanisms and therapeutic targets; develop new or refine existing models and research tools; identify or validate biomarkers; evaluate the effectiveness of therapies, including pharmaceuticals, electroceuticals, digital therapies, or cognitive and behavioral health interventions to prevent the onset of or promote recovery from neuropsychiatric disorders; characterize similarities and differences between two or more neuropsychiatric or neurotraumatic disorders to advance personalized medicine; improve understanding of how comorbid conditions such as cancer and diabetes, as well as other neurological and non-neurological disorders, interact with neuropsychiatric disorders and impact diagnosis, prognosis, and treatments; promote or restore brain health by conducting bi-directional and/or iterative translational research using existing clinical data or new data from small pilot clinical studies in combination with relevant preclinical or computational models; or advance digital health, telehealth, or other innovative approaches to increasing access to mental health care.

A single grant of up to $8,000 grant will be awarded to support novel basic and clinical research on anxiety and anxiety related disorders conducted by graduate students and early career researchers. To be eligible, applicants must be a graduate student or early-career researcher (no more than ten years postdoctoral); be affiliated with a nonprofit charitable, educational, or scientific institution, or a governmental entity operating exclusively for charitable and educational purposes; have a demonstrated knowledge of anxiety and anxiety research, either basic or clinical; and have demonstrated competence and the capacity to execute the proposed work.

The American Psychological Foundation is accepting applications for its David H. And Beverly A. Barlow Grant. Through the program, a single grant of up to $7,500 will support novel basic and clinical research on anxiety and anxiety-related disorders conducted by a graduate student or early-career researcher. To be eligible for the grant, applicants must be a graduate student or early-career researcher (no more than ten years postdoctoral) and be affiliated with a nonprofit charitable, educational, or scientific institution or a governmental entity operating exclusively for charitable and educational purposes. See the American Psychological Foundation website for complete program guidelines and application instructions.

AFSP is committed to funding innovative research in all areas related to suicide. In an effort to stimulate research in understudied areas, we select priority areas for funding. Our two-year priority period allows for resubmission of unsuccessful applications in the second year. Priority area research applications are reviewed along with the general pool of grant applications, with priority given to strong grants in the designated areas. We aim to fund at least one to two rigorously designed priority area grants among those awarded in each cycle. While we encourage applications in our priority areas, we also encourage and welcome all applications related to preventing suicide. Our AFSP Suicide Research Grants Program Priority Areas for 2013-14 are Anxiety Disorders or Alcohol and Other Substance Use Disorders. These disorders may be studied alone or in combination with other disorders.

The purpose of this Funding Opportunity Announcement (FOA) is to support the early stage testing of pharmacologic interventions with novel mechanisms of action or device-based interventions, for the treatment of symptoms or domains of altered functions in individuals with mental illness (e.g. schizophrenia, depression, autism, obsessive compulsive disorder, anxiety, bipolar disorder, etc.). Early intervention studies are also encouraged where symptoms of a disorder have been identified in subjects (a prodromal phase), prior to full diagnostic criteria being met. Ultimately, this FOA is intended to support early stage testing of pharmacologic or device-based interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested, to provide meaningful information where target modulation yields a dose-dependent neurophysiological/clinical/behavioral effect. Pediatric, adult and geriatric focused interventions are appropriate for this FOA. This R33 FOA supports single phased clinical trial awards. Applicants proposing high risk projects are encouraged to apply to the companion FOA, RFA-MH-17-600. Also listed under R61/R33

To be eligible, applicants must be a graduate student or early-career researcher (no more than ten years postdoctoral); be affiliated with a nonprofit charitable, educational, or scientific institution, or a governmental entity operating exclusively for charitable and educational purposes; have a demonstrated knowledge of anxiety and anxiety research, either basic or clinical; and have demonstrated competence and the capacity to execute the proposed work.

The NARSAD Young Investigator Grant provides support for the most promising young scientists conducting neurobiological research. Two year awards up to $60,000, or $30,000 per year are provided to enable promising investigators to either extend research fellowship training or begin careers as independent research faculty. Basic and/or clinical investigators are supported, but research must be relevant to serious brain and behavior disorders such as schizophrenia, mood disorders, anxiety disorders, or child and adolescent mental illnesses. A few NARSAD Young Investigators are selected each year to present at the foundation's annual Scientific Symposium in New York City. NARSAD Young Investigators are also eligible to be selected for the Foundation's Freedman Prize for Outstanding Basic Research and Klerman Prize for Outstanding Clinical Research. Selection is based upon outstanding research as outlined in the final progress report of the NARSAD Grant project.

The ADAA Career Development Travel Awards are given to help early career professionals who have a research interest in anxiety disorders and depression, such as basic and clinical neurobiology, psychopharmacology, anxiety comorbidities, clinical psychology, genetics, neuroimaging, epidemiology, comparative effectiveness, multicultural issues, public health, as well as other areas. The awards also familiarize and engage aspiring professionals with the membership and work of the association.

This Funding Opportunity Announcement (FOA) encourages applications for mechanistic research on age-related changes in emotion regulation and how they may contribute to mental disorders in middle-aged and older adults.In particular, research is sought that will advance understanding of irregularities in the integrative neural-behavioral mechanisms of emotion regulation in adult mood and anxiety disorders, and that will examine whether the irregularities are associated with typical or atypical maturational trajectories of emotion processing. If older adults who suffer episodes of affective dysregulation share the same patterns of improved emotional function with age as have been found to be typical of the older adult population in general. Research that helps to clarify whether they do or do not manifest typical emotion processing trajectories may lead to very different understanding of the irregularities involved their dysregulation.It is anticipated that such studies may identify novel targets for mental health interventions or prevention efforts, or provide clues as to which available intervention strategies might be optimally applied to normalize emotion dysregulation or to strengthen emotional resilience at particular stages of the adult life cycle.

This Funding Opportunity Announcement (FOA) encourages applications for mechanistic research on age-related changes in emotion regulation and how they may contribute to mental disorders in middle-aged and older adults.In particular, research is sought that will advance understanding of irregularities in the integrative neural-behavioral mechanisms of emotion regulation in adult mood and anxiety disorders, and that will examine whether the irregularities are associated with typical or atypical maturational trajectories of emotion processing. If older adults who suffer episodes of affective dysregulation share the same patterns of improved emotional function with age as have been found to be typical of the older adult population in general, understanding of the irregularities involved their dysregulation.It is anticipated that such studies may identify novel targets for mental health interventions or prevention efforts, or provide clues as to which available intervention strategies might be optimally applied to normalize emotion dysregulation or to strengthen emotional resilience at particular stages of the adult life cycle.

This Funding Opportunity Announcement (FOA) encourages applicants to develop innovative research applications on prescription drug abuse, including research to examine the factors contributing to prescription drug abuse; to characterize the adverse medical, mental health and social consequences associated with prescription drug abuse; and to develop effective prevention and service delivery approaches and behavioral and pharmacological treatments. Applications to address these issues are encouraged across a broad range of methodological approaches including basic science, clinical, epidemiological, and health services research to define the extent of the problem of prescription drug abuse, to characterize this problem in terms of classes of drugs abused and combinations of drug types, etiology of abuse, and populations most affected (including analyses by age group, race/ethnicity, gender, and psychiatric symptomatology). Studies on individual- and patient-level factors, prescriber factors, and/or health system factors are encouraged, as are studies on all classes of prescription drugs with high abuse liability, including analgesics, stimulants, sedative/hypnotics and anxiolytics. Researchers are further encouraged to study the relationship between the prescription medication, the indication for which the medication was prescribed (e.g., pain, sleep disorder, anxiety disorder, obesity), and the environmental and individual factors contributing to abuse.

The purpose of this funding opportunity announcement (FOA) is to encourage research to integrate/harmonize existing data sets from preventive intervention trials implemented early in life to: 1) examine risk and protective factors relevant to later mental health outcomes in childhood, adolescence and young adulthood; and 2) determine whether preventive interventions delivered earlier in life have long-term effects, and/or cross-over effects (e.g., unanticipated beneficial effects), on important mental health outcomes, including serious mental illness (e.g., depression, anxiety, suicide ideation and behaviors, psychosis behaviors).